Literature DB >> 12970393

Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression.

Isabelle Passagne1, Alexandre Evrard, Jean-Yves Winum, Philippe Depeille, Pierre Cuq, Jean-Louis Montero, Didier Cupissol, Laurence Vian.   

Abstract

Fotemustine is a third generation chloroethylnitrosourea that has demonstrated significant antitumoral effects in malignant melanoma. However, its use is somewhat limited by its toxic side effects and chemoresistance caused by direct repair of O6-alkyl groups by the enzyme O6-methylguanine DNA-methyltransferase (MGMT). The aim of this work was to determine to what extent the expression of MGMT influences cytotoxicity, DNA damage, and apoptosis induced by new nitrososulfamide analogs of fotemustine (compounds 4 and 8), which have previously demonstrated interesting antiproliferative properties. We carried out complementary strategies that consisted of MGMT cDNA transfection in CAL77 Mer- melanoma cells and of MGMT inhibition with O6-benzylguanine (BG) in A375 Mer+ melanoma cells. MGMT-transfected cells were 7 to 9 times less sensitive to fotemustine than parent cells, whereas no difference between the transfected and parent cells was observed for nitrososulfamide analogs. The cytotoxicity of these analogs vis à vis a MGMT-proficient A375 melanoma cell line was approximately 3 times greater than that of fotemustine. Coincubation of these cells with O6-benzylguanine significantly increased the cytotoxicity of fotemustine and compound 8, whereas BG had little effect on the cytotoxicity of compound 4. Furthermore, DNA fragmentation determined by a comet assay was greater with nitrososulfamide analogs than with fotemustine. O6-benzylguanine increased DNA fragmentation for fotemustine and compound 8, but not for compound 4, which induced comets with a typical apoptotic appearance. The ability of this compound to induce apoptosis in the absence of BG was confirmed by a specific enzyme-linked immunosorbent assay apoptotic assay using a single-stranded DNA monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970393     DOI: 10.1124/jpet.103.051938

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  tert-Butyl N-[N,N-bis-(2-chloro-ethyl)sulfamo-yl]-N-(2-chloro-ethyl)carbamate.

Authors:  Achour Seridi; Hocine Akkari; Jean-Yves Winum; Patricia Bénard-Rocherullé; Mohamed Abdaoui
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-09-26

2.  Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.

Authors:  Gaetano Corazzelli; Ferdinando Frigeri; Manuela Arcamone; Luigi Aloj; Gaetana Capobianco; Cristina Becchimanzi; Emanuela Morelli; Francesco Volzone; Gianpaolo Marcacci; Filippo Russo; Rosaria De Filippi; Secondo Lastoria; Antonio Pinto
Journal:  Eur J Haematol       Date:  2011-07-31       Impact factor: 2.997

3.  DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.

Authors:  Alessia Stornetta; Maike Zimmermann; George D Cimino; Paul T Henderson; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2017-01-03       Impact factor: 3.739

4.  Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.

Authors:  S C Naumann; W P Roos; E Jöst; C Belohlavek; V Lennerz; C W Schmidt; M Christmann; B Kaina
Journal:  Br J Cancer       Date:  2009-01-06       Impact factor: 7.640

5.  Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation.

Authors:  Aleksandra M Ristić-Fira; Lela B Korićanac; Jelena J Zakula; Lucia M Valastro; Gioacchin Iannolo; Giuseppe Privitera; Giacomo Cuttone; Ivan M Petrović
Journal:  J Exp Clin Cancer Res       Date:  2009-04-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.